SHARP HEALTHCARE

Novo Nordisk's Wegovy, approved by the FDA for preventing heart attacks and strokes, could benefit 44M more patients, per Dandelion Health's AI study. Using real-world data, AI identified lower-risk patients who could see reduced cardiovascular risks with GLP-1 treatment, potentially speeding up research and expanding drug applications.

Dandelion Health, founded by Mullainathan, Obermeyer, Gandhi, and Green, aims to improve healthcare through AI by collecting high-quality clinical data. They developed the Clinical AI Marketplace, which evaluates real-world data to validate AI algorithms, potentially speeding up drug approvals and improving clinical decisions. Their approach, using multimodal data and machine learning, could revolutionize healthcare by providing more accurate predictions and insights.